Rhythm Pharma Files 8-K for Regulation FD Disclosure
Ticker: RYTM · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1649904
| Field | Detail |
|---|---|
| Company | Rhythm Pharmaceuticals, Inc. (RYTM) |
| Form Type | 8-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-governance
TL;DR
**Rhythm Pharma just dropped an 8-K for Regulation FD, so expect news that could move the stock.**
AI Summary
Rhythm Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, under Regulation FD Disclosure, indicating they made a public announcement of material non-public information. This filing ensures that all investors receive important company updates simultaneously, preventing unfair trading advantages. For investors, this means the company is transparently sharing significant news, which could impact stock valuation depending on the nature of the disclosed information.
Why It Matters
This filing signals that Rhythm Pharmaceuticals has released material information to the public, which could influence investor decisions and the company's stock price (RYTM).
Risk Assessment
Risk Level: low — This 8-K filing is a procedural disclosure under Regulation FD, indicating transparency rather than a specific negative event.
Analyst Insight
A smart investor would monitor for the specific information disclosed under Regulation FD, as this 8-K only signals that such a disclosure has occurred, not its content. The actual impact will depend on the nature of the news.
Key Players & Entities
- RHYTHM PHARMACEUTICALS, INC. (company) — the registrant filing the 8-K
- January 4, 2024 (date) — date of earliest event reported and filing date
- 001-38223 (other) — Commission File Number
- RYTM (other) — trading symbol for Common Stock
- The Nasdaq Stock Market LLC (Nasdaq Global Market) (other) — exchange where Common Stock is registered
FAQ
What is the purpose of Rhythm Pharmaceuticals, Inc.'s 8-K filing on January 4, 2024?
The purpose of Rhythm Pharmaceuticals, Inc.'s 8-K filing on January 4, 2024, is for 'Regulation FD Disclosure', meaning they are publicly disclosing material non-public information to ensure fair access for all investors.
What is the trading symbol and exchange for Rhythm Pharmaceuticals, Inc.'s common stock?
The trading symbol for Rhythm Pharmaceuticals, Inc.'s common stock is RYTM, and it is registered on The Nasdaq Stock Market LLC (Nasdaq Global Market).
What is the business address of Rhythm Pharmaceuticals, Inc. as stated in the filing?
The business address of Rhythm Pharmaceuticals, Inc. is 222 Berkeley Street, 12th Floor, Boston, MA 02116.
Under which SEC Act was this 8-K filed?
This 8-K was filed under the Securities Exchange Act of 1934, specifically pursuant to Section 13 or 15(d).
What was Rhythm Pharmaceuticals, Inc.'s former company name and when did it change?
Rhythm Pharmaceuticals, Inc.'s former company name was RHYTHM METABOLIC, INC., and the date of the name change was August 3, 2015 (20150803).
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-01-04 07:15:39
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share RYTM The Nasdaq
Filing Documents
- tm2332524d3_8k.htm (8-K) — 22KB
- 0001104659-24-001141.txt ( ) — 189KB
- rytm-20240104.xsd (EX-101.SCH) — 3KB
- rytm-20240104_lab.xml (EX-101.LAB) — 33KB
- rytm-20240104_pre.xml (EX-101.PRE) — 22KB
- tm2332524d3_8k_htm.xml (XML) — 3KB
01
Item 7.01. Regulation FD Disclosure. On January 4, 2024, Rhythm Pharmaceuticals, Inc. posted a corporate slide presentation to reflect recent business and financial updates. The updated slide presentation can be found in the "Investor Relations" portion of the website at ir.rhythmtx.com. The information contained in Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: January 4, 2024 By: /s/ Hunter Smith Hunter Smith Chief Financial Officer